Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIxico Regulatory News (IXI)

Share Price Information for Ixico (IXI)

Share Price is delayed by 15 minutes
Get Live Data
8.65    0.00 (0.00%)
Bid:
8.30
Ask:
9.00
Spread: 0.70 (8.434%)
Market Cap: £18.86m
IXI Live PriceLast checked at - London Stock Exchange

Intraday Ixico Share Chart

Director/PDMR Shareholding

19 Jan 2011 14:14

RNS Number : 7525Z
Phytopharm PLC
19 January 2011
 

 

Annex DTR3

 

Notification of Transactions of Directors/Persons Discharging Managerial Responsibility and Connected Persons

 

 

All relevant boxes should be completed in block capital letters.

 

1.

Name of the issuer

PHYTOPHARM PLC

2.

State whether the notification relates to (i) a

transaction notified in accordance with DTR 3.1.2 R,

(ii) a disclosure made in accordance

LR 9.8.6R(1) or

(iii) a disclosure made in accordance with section 793 of the Companies Act (2006).

BOTH (i) AND (ii)

3.

Name of person discharging managerial

responsibilities/director

MR ROGER HICKLING, RESEARCH AND DEVELOPMENT DIRECTOR

 

4.

State whether notification relates to a person

connected with a person discharging managerial responsibilities/director named in 3 and identify the connected person

AS 3 ABOVE

5.

Indicate whether the notification is in respect of a holding of the person referred to in 3 or 4 above or in respect of a nonbeneficial

interest 1

AS 3 ABOVE

6.

Description of shares (including class), debentures or derivatives or financial instruments relating to shares

ORDINARY SHARES OF 1 PENCE EACH

7.

Name of registered shareholders(s) and, if more than one, the number of shares held by each of them

AS ABOVE

8.

State the nature of the transaction

SHARES ACQUIRED

 

9.

Number of shares, debentures or financial

instruments relating to shares acquired

120,000 ORDINARY SHARES

10.

Percentage of issued class acquired (treasury shares of that class should not be taken into account when calculating percentage)

0.035%

 

11.

Number of shares, debentures or financial

instruments relating to shares disposed

12.

Percentage of issued class disposed (treasury shares of that class should not be taken into account when calculating percentage)

 

13.

Price per share or value of transaction

8.3 PENCE PER ORDINARY SHARE

 

 

14.

Date and place of transaction

19 JANUARY 2011, LONDON

 

 

15.

Total holding following notification and total percentage holding following notification (any treasury shares should not be taken into account when calculating percentage)

120,000 - 0.035%

16.

Date issuer informed of transaction

19 JANUARY 2011

 

 

 

 

If a person discharging managerial responsibilities has been granted options by the issuer

complete the following boxes

 

17.

Date of grant

 

18.

Period during which or date on which exercisable

 

19.

Total amount paid (if any) for grant of the option

 

20.

Description of shares or debentures involved (class and number)

 

21.

Exercise price (if fixed at time of grant) or

indication that price is to be fixed at the time of exercise

 

22.

Total number of shares or debentures over which options held following notification

 

23.

Any additional information

 

24.

Name of contact and telephone number for queries

ZOE MCGOWANCOMPANY SECRETARY01480 437697

 

 

Name of authorised official of issuer responsible for making notification

ZOE MCGOWAN, COMPANY SECRETARY

Date of notification 19 JANUARY 2011

 

 

 

Notes: This form is intended for use by an issuer to make a RIS notification required by DR 3.3.

 

(1)

An issuer making a notification in respect of a transaction relating to the shares or debentures of the issuer should complete boxes 1 to 16, 23 and 24.

(2)

An issuer making a notification in respect of a derivative relating the shares of the issuer should complete boxes 1 to 4, 6, 8, 13, 14, 16, 23 and 24.

(3)

An issuer making a notification in respect of options granted to a director/person discharging managerial responsibilities should complete boxes 1 to 3 and 17 to 24.

(4)

An issuer making a notification in respect of a financial instrument relating to the shares of the issuer (other than a debenture) should complete boxes 1 to 4, 6, 8, 9, 11, 13, 14, 16, 23 and 24.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSBLMITMBBBBTB
Date   Source Headline
3rd May 20187:00 amRNSPlacing to raise ?5.5 million
4th Apr 20187:00 amRNSAgreement
30th Jan 20187:00 amRNSNew contract in progressive supranuclear palsy
22nd Jan 20183:16 pmRNSResult of AGM
22nd Jan 20187:00 amRNSAGM Statement and Board Changes
11th Dec 20177:00 amRNSFinal Results
28th Nov 20177:00 amRNSStrategic and Operational Update
16th Nov 20177:00 amRNSContract to Deploy Biosensors in Clinical Trial
19th Oct 201710:14 amRNSTrading Statement
4th Oct 20177:00 amRNSNew contract to support Phase II clinical trial
28th Sep 20177:00 amRNSNew contract in Huntington's disease
25th Sep 20177:00 amRNSNew Contract with Biopharmaceutical Company
5th Sep 20177:00 amRNSExtension of a 5 year contract
8th Aug 20174:23 pmRNSDirector/PDMR Shareholding
24th Jul 20177:00 amRNSExpansion of Collaboration with Biogen
18th Jul 20177:00 amRNSIXICO hosts Alzheimer Expert Symposium
5th Jul 20177:00 amRNSNew contract for imaging clinical trial services
22nd May 20177:00 amRNSHalf Yearly Report to 31 March 2017
16th May 20179:57 amRNSNotice of H1 Results
12th Apr 201712:41 pmRNSExercise of share options
29th Mar 20173:30 pmRNSDirector/PDMR Shareholding
29th Mar 20173:30 pmRNSDirector/PDMR Shareholding
29th Mar 20173:30 pmRNSExercise of Share Options
13th Mar 20177:00 amRNSIXICO signs US$1.5m contract
10th Mar 201710:00 amRNSTo present novel sleep measurement technology
9th Feb 20177:00 amRNSGrant of Share Options
30th Jan 201710:28 amRNSResult of AGM
17th Jan 20174:09 pmRNSDirector/PDMR Shareholding
17th Jan 20177:00 amRNSAppointment of Giulio Cerroni as CEO
16th Jan 20172:00 pmRNSAnnual Report and Accounts and Notice of AGM
13th Jan 20173:25 pmRNSHolding(s) in Company
12th Jan 20172:56 pmRNSHolding(s) in Company
4th Jan 20173:43 pmRNSIssue of 590,093 Deferred Consideration Shares
23rd Dec 20167:00 amRNSBuyback and Cancellation of Deferred Shares
20th Dec 20167:00 amRNSFull Year Results
16th Nov 20167:00 amRNSParticipation in major EU partnership (ROADMAP)
21st Oct 20167:00 amRNSPre-Close Trading Update
20th Oct 20167:00 amRNS$1.2m contract with new global pharma customer
19th Oct 20167:00 amRNSIXICO presents at CAMD regulatory workshop
10th Oct 20167:00 amRNSEUR1m funding as a partner in major EU consortium
3rd Oct 20167:00 amRNSAppointment of Shore Capital as Nominated Adviser
3rd Oct 20167:00 amRNSAppointment of Shore Capital
26th Sep 20165:14 pmRNSDirector/PDMR Shareholding
26th Sep 20161:58 pmRNSExercise of Share Options
16th Sep 20167:00 amRNSBoard changes
13th Sep 20167:00 amRNSPresentation of Assessa® PML at ECTRIMS
29th Jul 201610:25 amRNSWeb-Based Technology Improves Paediatric ADHD Care
7th Jun 20167:00 amRNSHalf Yearly Report to 31 March 2016
2nd Jun 20167:00 amRNSCygnus joins Dementias Platform UK
4th Apr 20167:00 amRNSConsortium and Five Year Contract

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.